Ross Dobie

Ross Dobie

UNVERIFIED PROFILE

Are you Ross Dobie?   Register this Author

Register author
Ross Dobie

Ross Dobie

Publications by authors named "Ross Dobie"

Are you Ross Dobie?   Register this Author

9Publications

81Reads

45Profile Views

Suppressor of cytokine signaling 2 () deletion protects bone health of mice with DSS-induced inflammatory bowel disease.

Dis Model Mech 2018 01 17;11(1). Epub 2018 Jan 17.

Division of Developmental Biology, The Roslin Institute and Royal (Dick) School of Veterinary Studies, University of Edinburgh, Easter Bush, Roslin, Midlothian, Edinburgh EH25 9RG, UK

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1242/dmm.028456DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5818069PMC
January 2018

Homing in on the hepatic scar: recent advances in cell-specific targeting of liver fibrosis.

F1000Res 2016 19;5. Epub 2016 Jul 19.

MRC Centre for Inflammation Research, The Queen's Medical Research Institute, University of Edinburgh, Edinburgh, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12688/f1000research.8822.1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4955024PMC
August 2016

PAK proteins and YAP-1 signalling downstream of integrin beta-1 in myofibroblasts promote liver fibrosis.

Nat Commun 2016 08 18;7:12502. Epub 2016 Aug 18.

Centre for Endocrinology and Diabetes, Institute of Human Development, Faculty of Medical and Human Sciences, University of Manchester, Manchester Academic Health Sciences Centre, Manchester M13 9PT, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ncomms12502DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4992158PMC
August 2016

Increased linear bone growth by GH in the absence of SOCS2 is independent of IGF-1.

J Cell Physiol 2015 Nov;230(11):2796-806

The Roslin Institute and R(D)SVS, University of Edinburgh, Easter Bush, Midlothian, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jcp.25006DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4949688PMC
November 2015

Piroxicam treatment augments bone abnormalities in interleukin-10 knockout mice.

Inflamm Bowel Dis 2015 Feb;21(2):257-66

*Novo Nordisk-LIFE In Vivo Pharmacology Centre, Frederiksberg, Denmark; †Developmental Endocrinology Research Group, School of Medicine, Royal Hospital for Sick Children, University of Glasgow, Glasgow, United Kingdom; ‡Department of Veterinary Disease Biology, Faculty of Health and Medical Sciences, University of Copenhagen, Frederiksberg, Denmark; §Division of Developmental Biology, The Roslin Institute, University of Edinburgh, Edinburgh, United Kingdom; ‖Department of Musculoskeletal Biology, Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, United Kingdom; and ¶Department of Immunopharmacology, Novo Nordisk A/S, Maaloev, Denmark.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MIB.0000000000000269DOI Listing
February 2015